Posted on: May 1, 2020 Posted by: admin Comments: 0

ANCOBON PRESCRIBING INFORMATION PDF

Package Insert-Flucytosine * Ancobon® is a The appropriate approved prescribing information should be consulted. Images. Group: antifungal. Capsule, mg [EDL] Solution for injection, g in ml [ EDL]. General information. Flucytosine is a fluorinated pyrimidine, non-antibiotic . Related Drug Information Flucytosine must be given with extreme caution to patients with bone marrow suppression. of America (IDSA) recommends 25 mg /kg/dose PO 4 times daily in combination with a lipid amphotericin B product.

Author: Faulrajas Vijin
Country: Czech Republic
Language: English (Spanish)
Genre: Finance
Published (Last): 15 September 2006
Pages: 399
PDF File Size: 19.3 Mb
ePub File Size: 5.33 Mb
ISBN: 810-4-82171-657-3
Downloads: 72235
Price: Free* [*Free Regsitration Required]
Uploader: Dora

Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Flucytosine. Canakinumab The risk or severity of adverse effects can be increased when Flucytosine is combined with Canakinumab. The risk or severity of neutropenia and thrombocytopenia can be increased ptescribing Chlorothiazide is combined with Flucytosine.

Rilonacept The risk or severity of adverse effects can be increased when Flucytosine is combined with Rilonacept. Marketing authorisation holder 8.

Flucytosine Capsules, USP | Rising Pharmaceuticals

The risk or severity of adverse effects can be increased when Flucytosine is combined with Briakinumab. The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydrocortisone succinate.

Clostridium tetani toxoid antigen formaldehyde inactivated The therapeutic efficacy of Clostridium tetani toxoid antigen formaldehyde inactivated can be decreased when used in combination with Flucytosine. Dinutuximab The risk or severity of adverse effects can be increased when Flucytosine is combined with Dinutuximab. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Flucytosine.

Fluperolone The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluperolone. The risk or severity of adverse effects can be increased when Doxorubicin is combined with Flucytosine. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Flucytosine. Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.

  LIBRO PROGRAMACION EN C BYRON GOTTFRIED PDF

Flucytosine may interfere with the dual-slide enzymatic measurement of creatinine used with the manual desk top Vitros DT 60 analyser, giving the false impression of azetomia.

Fluticasone The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluticasone. The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Flucytosine.

Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Flucytosine. Lipegfilgrastim Flucytosine may increase the myelosuppressive activities of Lipegfilgrastim. If Ancotil is administered in pregnancy, the patient should be advised of the teratogenic risk of Ancotil, and careful prenatal and postnatal monitoring should be performed.

The risk or severity of adverse effects can be increased when Natalizumab is combined with Flucytosine. Flucytosine penetrates fungal cells, where it is deaminated to fluorouracil by the fungal enzyme cytosine deaminase. The risk or severity of adverse effects can be increased when Flucytosine is combined with Eribulin. The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydrocortisone aceponate.

Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Flucytosine. The risk or severity of bleeding can be increased when Linsidomine is combined with Flucytosine.

Ancotil 2.5g/250ml Solution for Infusion

The risk or severity of bleeding can be increased when Potassium Citrate is combined with Flucytosine. The risk or severity of adverse effects can be increased when Leflunomide is combined with Flucytosine.

Treatment should continue until all signs and symptoms and CSF and radiologic abnormalities have resolved. Particular attention should be paid to renal function in this group. Flucytosine crosses the human placenta. We do not record any personal information entered above. The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Flucytosine. Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Flucytosine.

  CAUSAS QUILOTORAX PDF

The risk or severity of adverse effects can be increased when Flucytosine is combined with Castanospermine. The risk or severity of bleeding can be increased when Protein S human is combined with Flucytosine. The risk or severity of adverse effects can be increased when Irinotecan is combined with Flucytosine.

Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Flucytosine.

The risk or severity of adverse effects can be increased when Flucytosine is combined with Abetimus. Although flucytosine is metabolized to 5-fluorouracil, flucytosine itself does not possess antineoplastic activity. Fungi that usually are susceptible include: Hydrocortisone The prscribing or severity of adverse effects can be increased informatoon Hydrocortisone is combined with Flucytosine.

The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluclorolone. If a breast-feeding infant experiences an adverse effect related to a maternally ingested or administered drug, health care providers are encouraged to report the adverse effect to the FDA.

The risk or severity of adverse effects can be increased when Bleomycin is combined with Flucytosine. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Flucytosine.

Minor Flucytosine can cause significant hematologic toxicity. The rats were administered doses ranging from 0.

Fluorodeoxyuridine interferes with the enzyme thymidylate synthase. Fluocortolone The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluocortolone. Peak plasma concentrations are reached within 1 — 2 hours after oral administration but may be delayed in subjects with renal impairment to 4 – informatioj hours.

Categories:

Leave a Comment